BioType
Private Company
Total funding raised: $2.5M
Overview
BioType is a commercial-stage, private German diagnostics company specializing in molecular precision diagnostics for hemato-oncology and clinical research. Its business is built on a proprietary multi-biomarker testing platform (MODAPLEX) and a portfolio of CE-marked IVD kits for Acute Myeloid Leukemia (AML) profiling and chimerism monitoring post-transplant. The company is actively expanding its commercial reach through new distribution partnerships across Europe and is engaged in the local Saxony life sciences ecosystem, indicating a focus on growth and collaboration.
Technology Platform
Proprietary MODAPLEX Platform: a benchtop system for integrated, comprehensive multi-biomarker testing in a single workflow. Supports multiplexed molecular analysis for clinical diagnostics and research.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
BioType competes in the specialized molecular diagnostics for oncology space. Key competitors include large, diversified IVD companies like Roche, Abbott, and Qiagen, which offer broad oncology panels, as well as smaller niche players and the overarching disruptive threat of comprehensive NGS-based profiling solutions from companies like Illumina and Thermo Fisher.